DDInter997 DDInter1747
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Ivacaftor {u} (Compound) binds {v} (Gene) CYP3A4
Ivacaftor {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ivacaftor {u} (Compound) causes {v} (Side Effect) Pleuritic pain
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avapritinib
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ivacaftor (Compound) binds CYP3A4 (Gene)
Ivacaftor (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ivacaftor (Compound) causes Pleuritic pain (Side Effect)
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ivacaftor may lead to a major life threatening interaction when taken with Fluconazole
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib